Dendreon Announces Phase I Study Results for APC8024 Immunotherapy to be Presented at ASCO.Business Editors/Health/Medical Writers BIOWIRE2K 2004 American Society of Clinical Oncology American Society of Clinical Oncology, or ASCO, is an organization that represents all clinical oncologists. Every year, ASCO holds a large symposium where physicians and researchers meet to convey and discuss research and ideas. Annual Meeting SEATTLE--(BUSINESS WIRE)--June 3, 2004 Dendreon Corporation (Nasdaq:DNDN) today announced the scheduled presentation of an abstract at the 40th American Society of Clinical Oncology (ASCO ASCO American Society of Clinical Oncology ASCO Association of Schools and Colleges of Optometry (since 1941; Rockville, Maryland) ASCO Australian Standard Classification of Occupations ASCO Automatic Switch Company ) Meeting to be held in New Orleans New Orleans (ôr`lēənz –lənz, ôrlēnz`), city (2006 pop. 187,525), coextensive with Orleans parish, SE La., between the Mississippi River and Lake Pontchartrain, 107 mi (172 km) by water from the river mouth; founded , Louisiana from June 5-8, 2004. Dendreon Corporation will also host booth #2139 at the meeting. Details are as follows. Antigen Presenting Cell Based Immunotherapy Targeting HER2/Neu Positive Solid Tumors: Results of a Phase 1 Study of APC (1) (American Power Conversion Corporation, West Kingston, RI, www.apcc.com) The leading manufacturer of UPS systems and surge suppressors, founded in 1981 by Rodger Dowdell, Neil Rasmussen and Emanual Landsman, three electronic power engineers who had worked at MIT. 8024. Poster Presentation: Monday, June 7, 2004, 8:00 a.m.-12:00 p.m. (Abstract #2528) Presenter: Prema Peethambaram, MD, Mayo Clinic Mayo Clinic: see Mayo, Charles Horace. Mayo Clinic voluntary association of more than 500 physicians in Rochester, Minnesota. [Am. Hist.: EB, 11: 723] See : Medicine College of Medicine, Rochester, MN This abstract may be accessed online at www.asco.org at the conclusion of the meeting. The poster presentations will not be web cast. APC8024 is an immunotherapy that targets tumors that express the HER2/neu marker. In humans, HER2/neu is overexpressed in a variety of solid tumors, including breast, colon and ovarian cancer ovarian cancer Malignant tumour of the ovaries. Risk factors include early age of first menstruation (before age 12), late onset of menopause (after age 52), absence of pregnancy, presence of specific genetic mutations, use of fertility drugs, and personal history of breast . APC8024 uses Dendreon's proprietary Antigen Delivery Cassette(TM) technology to genetically engineer antigens such as HER2/neu to bind to to contract; as, to bind one's self to a wife s>. See also: Bind antigen presenting cells and stimulate T-cell immunity. Treatment consists of three infusions of APC8024 over the course of a one-month period. The APC8024 approach is similar to the approach used in the development of Provenge(R), another targeted immunotherapy that has produced promising results to date in clinical trials for the treatment of prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. Provenge is currently in a pivotal Phase 3 clinical trial phase 3 clinical trial Phase 3 study. See Phase study. . About ASCO The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians who treat people with cancer. ASCO's members set the standard for patient care worldwide and lead the fight for more effective cancer treatments, increased funding for clinical and translational research, and, ultimately, cures for the many different cancers that strike millions of people around the world every year. About Dendreon Dendreon Corporation is a biotechnology company developing targeted therapies for cancer. In addition to its immunotherapies in clinical and preclinical development for a variety of cancers, Dendreon's product pipeline also includes monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing and small molecule product candidates. Dendreon has research and development alliances with Genentech, Inc., Abgenix, Inc. and Dyax Corp. For more information about the company and its programs, visit www.dendreon.com. Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such a difference include risks associated with completing Dendreon's clinical trials, the risk that the safety and/or efficacy results of a clinical trial will not support further clinical trials or an application for a biologics license, the risk that the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. will not approve a product for which a biologics license has been applied, the failure by Dendreon to secure and maintain relationships with collaborators, dependence on the efforts of third parties, dependence on intellectual property, risks related to Dendreon's limited operating history and risks related to the uncertainty of Dendreon's future access to capital. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations, are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion